Zymeworks (ZYME) EVP Schayowitz Adam Sells $358K of Stock

Adam Schayowitz, the Executive Vice President and Head of R&D at Zymeworks Inc. (NasdaqGS: ZYME), sold 13,832 shares on October 9, 2026, for approximately $357,557. The sale price was $25.85 per share. This trade was not planned, according to the filing.

Inside Schayowitz's Trade

Schayowitz's sale of shares comes as the stock trades below its recent averages. The sale was significant given that it represented a notable amount relative to the company's typical insider activity. Zymeworks has faced challenges recently, which may have influenced this decision.

Other Institutional Activity in Zymeworks

Several institutional investors remain active in Zymeworks. EcoR1 Capital, LLC holds about 22,970,388 shares valued at approximately $574.9 million. Rubric Capital Management LP continues to hold 7 million shares worth about $175.2 million. Meanwhile, Blackrock Inc. reduced its position by 302,832 shares, now holding 4,251,030 shares valued at around $106.4 million. Perceptive Advisors LLC increased its stake by 672,881 shares, bringing its total to 4,182,953 shares worth about $104.7 million.

Zymeworks Inc. Stock Down 1.4%

Zymeworks shares recently traded around $25.38 as of October 16, 2026. This price is below the 50-day moving average of $26.71 and also 19% below its 52-week high of $31.34. The stock is currently about 58.6% above its 52-week low of $16.00, indicating some resilience despite recent volatility.

Recent Earnings

In its most recent earnings report, Zymeworks reported trailing twelve-month revenue of $37.1 million, but it faced a significant year-over-year revenue decline of 90.6%. The company is scheduled to report its next earnings on November 9, 2026.

Insider Buying and Selling at Zymeworks Inc.

Earlier this year, several insiders sold shares as well. Kenneth Harry Galbraith, the CEO, sold 30,424 shares at $22.67 each on January 12, 2026, totaling about $689,819. Paul Andrew Moore, another officer, sold 9,560 shares for $216,759 on the same date. Mark Hollywood, the COO, and FRCP Smith Jeffrey T L Md also made similar sales, indicating a trend of insider selling.

Analysts Set New Price Targets

Analysts have been optimistic about Zymeworks. On October 7, 2026, Truist Securities maintained a Buy rating with a price target of $34.0. Earlier, Citigroup raised its target to $39.0 on September 29, 2026, while JP Morgan set a target of $33.0 on September 3, 2026. The consensus target mean price is $41.21, reflecting a strong buy recommendation based on 14 analyst opinions.

About Zymeworks Inc.

Zymeworks Inc. is a biotechnology company based in Middletown, Delaware. It focuses on developing biotherapeutics for treating cancer, inflammation, and autoimmune diseases. The recent insider selling and analyst ratings suggest that the market is closely watching Zymeworks as it navigates its growth challenges.

Bottom Line

Investors should keep an eye on Zymeworks as it approaches its next earnings report on November 9, 2026, and monitor any additional insider trading activity. The ongoing analyst support could suggest potential recovery, but current trading levels remain below key averages.